**Invitation for Registered 503Bs (Compounding Outsourcing Facilities)**

We are reaching out to invite you to participate in the Compounding Outsourcing Facilities Survey. As part of its commitment to the compounding industry, the FDA is establishing the Compounding Quality Center of Excellence (CoE) which is focused on improving the quality of compounded drugs, primarily those made at outsourcing facilities. To help inform the development of the CoE, the FDA is inviting all compounding outsourcing facilities to provide insights, perspectives, and input on operational barriers and opportunities related to the outsourcing facility market, compliance with federal policies and good quality drug production, and interactions and engagement with FDA.

You can access the survey here: *{placeholder for survey tool link}*

The survey will take ~60 minutes to complete. All responses to the survey will be anonymous and non-attributable. The survey is being administered by a third party. While FDA will utilize the information obtained from your survey responses, FDA will not have any direct involvement with administering the survey or collecting and tabulating the results.

We look forward to hearing from you!